MX2024004647A - Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus. - Google Patents
Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus.Info
- Publication number
- MX2024004647A MX2024004647A MX2024004647A MX2024004647A MX2024004647A MX 2024004647 A MX2024004647 A MX 2024004647A MX 2024004647 A MX2024004647 A MX 2024004647A MX 2024004647 A MX2024004647 A MX 2024004647A MX 2024004647 A MX2024004647 A MX 2024004647A
- Authority
- MX
- Mexico
- Prior art keywords
- polynucleotides
- aav
- eukaryotic cells
- cells
- adenovirus
- Prior art date
Links
- 102000040430 polynucleotide Human genes 0.000 title abstract 6
- 108091033319 polynucleotide Proteins 0.000 title abstract 6
- 239000002157 polynucleotide Substances 0.000 title abstract 6
- 210000003527 eukaryotic cell Anatomy 0.000 title abstract 4
- 241000701161 unidentified adenovirus Species 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256730P | 2021-10-18 | 2021-10-18 | |
| PCT/US2022/078266 WO2023069926A1 (en) | 2021-10-18 | 2022-10-18 | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004647A true MX2024004647A (es) | 2024-05-02 |
Family
ID=84389146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004647A MX2024004647A (es) | 2021-10-18 | 2022-10-18 | Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12234472B2 (https=) |
| EP (1) | EP4419696A1 (https=) |
| JP (1) | JP2024537896A (https=) |
| KR (1) | KR20240099288A (https=) |
| CN (1) | CN118103517A (https=) |
| AU (1) | AU2022373653A1 (https=) |
| CA (1) | CA3234939A1 (https=) |
| IL (1) | IL312124A (https=) |
| MX (1) | MX2024004647A (https=) |
| TW (1) | TW202323529A (https=) |
| WO (1) | WO2023069926A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202515999A (zh) | 2023-06-20 | 2025-04-16 | 美商再生元醫藥公司 | 純化填充的腺相關病毒殼體之方法 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5985846A (en) | 1995-06-07 | 1999-11-16 | Baylor College Of Medicine | Gene therapy for muscular dystrophy |
| US7232899B2 (en) | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| WO1998054345A1 (en) | 1997-05-30 | 1998-12-03 | Baxter International Inc. | Mini-adenoviral vector |
| AU770005B2 (en) | 1998-04-15 | 2004-02-12 | Research Foundation Of The State University Of New York, The | Selective regulation of adenovirus production |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| US6423544B1 (en) | 1998-12-31 | 2002-07-23 | Chiron Corporation | Compositions and methods for producing recombinant virions |
| MY123548A (en) | 1999-11-08 | 2006-05-31 | Shell Int Research | Method and system for suppressing and controlling slug flow in a multi-phase fluid stream |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| US6558948B1 (en) | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
| EP1362096B1 (de) | 2001-02-21 | 2009-08-19 | CEVEC Pharmaceuticals GmbH | Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung |
| CA2485939C (en) | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| US8673589B2 (en) | 2002-05-29 | 2014-03-18 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| EP1743041B1 (en) | 2004-05-03 | 2012-06-27 | Stefan Kochanek | Modified viral vector particles |
| DE102005054628A1 (de) | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
| WO2007084773A2 (en) * | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
| EP2431469A3 (en) | 2006-05-15 | 2012-05-30 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| US8852926B2 (en) | 2007-10-25 | 2014-10-07 | Board Of Trustees Of Southern Illinois University | Genetic selection system for identification of MicroRNA target genes |
| DE102009003439A1 (de) | 2009-02-05 | 2010-08-26 | Cevec Pharmaceuticals Gmbh | Neue permanente humane Zelllinie |
| WO2010138263A2 (en) * | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| US20130023033A1 (en) | 2010-03-29 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US9839696B2 (en) | 2010-04-30 | 2017-12-12 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| SG187863A1 (en) | 2010-08-16 | 2013-03-28 | Cevec Pharmaceuticals Gmbh | Permanent human amniocyte cell lines for producing influenza viruses |
| EP2662451A1 (en) | 2012-05-07 | 2013-11-13 | Stefan Kochanek | Nucleic acid construct and use of the same |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| ES2698610T3 (es) | 2013-08-06 | 2019-02-05 | Lonza Biologics Plc | Medios y métodos para la generación de células productoras de mamífero para la producción de proteínas recombinantes |
| GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
| EP4410805A3 (en) | 2014-03-18 | 2024-11-27 | University of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| KR102243243B1 (ko) | 2014-10-23 | 2021-04-22 | 리제너론 파마슈티칼스 인코포레이티드 | 신규한 cho 통합 부위 및 이의 용도 |
| EP3042952A1 (en) | 2015-01-07 | 2016-07-13 | CEVEC Pharmaceuticals GmbH | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same |
| TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
| EP3205719A1 (en) | 2016-02-15 | 2017-08-16 | CEVEC Pharmaceuticals GmbH | Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins |
| GB201603577D0 (en) | 2016-03-01 | 2016-04-13 | Oxford Genetics Ltd | Promoter |
| MX2018011928A (es) | 2016-03-30 | 2019-03-28 | Spark Therapeutics Inc | Linea celular para produccion de proteina recombinante y/o vector viral. |
| US11512144B2 (en) | 2016-04-20 | 2022-11-29 | Regeneran Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing loci |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| US20190171188A1 (en) | 2016-08-10 | 2019-06-06 | Lonza Inc. | Biopharmaceutical Batch Recipe Review by Exception |
| JP7112414B2 (ja) | 2017-02-08 | 2022-08-03 | フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ | 網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ８８ |
| WO2018150269A1 (en) | 2017-02-17 | 2018-08-23 | Lonza Ltd. | Multi-site specific integration cells for difficult to express proteins |
| WO2018150271A1 (en) | 2017-02-17 | 2018-08-23 | Lonza Ltd. | Mammalian cells for producing adeno-associated viruses |
| KR20190129092A (ko) | 2017-03-17 | 2019-11-19 | 론자 리미티드 | 자동화된 배치 데이터 분석 |
| JP7142643B2 (ja) | 2017-03-22 | 2022-09-27 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | Ｈｄａｃ阻害剤またはｒｅｐタンパク質を伴う細胞培養方法 |
| EP3382014A1 (en) | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| GB201705927D0 (en) | 2017-04-12 | 2017-05-24 | Oxford Genetics Ltd | Vector |
| US10858631B2 (en) | 2017-04-18 | 2020-12-08 | Glaxosmithkline Intellectual Property Development Limited | Methods for adeno-associated viral vector production |
| CN110892064A (zh) | 2017-07-25 | 2020-03-17 | 牛津遗传学有限公司 | 腺病毒载体 |
| EP3441471A1 (en) | 2017-08-08 | 2019-02-13 | CEVEC Pharmaceuticals GmbH | Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines |
| EP3456822A1 (en) | 2017-09-19 | 2019-03-20 | CEVEC Pharmaceuticals GmbH | Inducible aav rep genes |
| WO2019073059A1 (en) | 2017-10-12 | 2019-04-18 | Freeline Therapeutics Limited | ADENOVIRAL AUXILIARY VIRUSES WITH DEFECTIVE CYCLE LIFE, PRODUCTION AND USE FOR THE PRODUCTION OF RAAV |
| JP7274225B2 (ja) | 2017-10-25 | 2023-05-16 | ノイスコム アーゲー | 真核細胞系統 |
| IL275462B2 (en) | 2017-12-22 | 2026-01-01 | Genentech Inc | Targeted integration of nucleic acids |
| GB201800903D0 (en) | 2018-01-19 | 2018-03-07 | Oxford Genetics Ltd | Vectors |
| WO2019157239A1 (en) | 2018-02-08 | 2019-08-15 | David Kiewlich | Plasmid vectors for expression of large nucleic acid transgenes |
| GB201802122D0 (en) | 2018-02-09 | 2018-03-28 | Univ Oxford Innovation Ltd | Product and use |
| GB201814590D0 (en) | 2018-09-07 | 2018-10-24 | Oxford Biomedica Ltd | Viral vector production system |
| EP3597172A1 (en) | 2018-07-16 | 2020-01-22 | Kao Germany GmbH | Hair treatment composition |
| WO2020041454A1 (en) | 2018-08-21 | 2020-02-27 | Lonza Ltd | A process for creating reference data for predicting concentrations of quality attributes |
| GB201814141D0 (en) | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
| JP7549582B2 (ja) | 2018-10-01 | 2024-09-11 | ロンザ リミテッド | 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法 |
| WO2020077411A1 (en) | 2018-10-17 | 2020-04-23 | Children's Medical Research Institute | Nucleic acid molecules and methods for aav vector selection |
| GB201816919D0 (en) | 2018-10-17 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Adeno-associated viral vector producer cell lines |
| EP3870604B1 (en) | 2018-10-26 | 2022-11-23 | F. Hoffmann-La Roche AG | Multispecific antibody screening method using recombinase mediated cassette exchange |
| KR20210108406A (ko) | 2018-12-21 | 2021-09-02 | 론자 워커스빌 아이엔씨. | 바이러스 벡터의 자동화된 생산 |
| AU2019403279A1 (en) | 2018-12-21 | 2021-07-01 | Genentech, Inc. | Targeted integration of nucleic acids |
| SG11202106217TA (en) * | 2018-12-21 | 2021-07-29 | Lonza Walkersville Inc | Adeno-associated virus (aav) producer cell line and related methods |
| GB201901571D0 (en) | 2019-02-05 | 2019-03-27 | Oxford Genetics Ltd | Inducible AAV sysyem |
| GB201902068D0 (en) | 2019-02-14 | 2019-04-03 | Cambridge Entpr Ltd | Methods of reactivating proliferative capacity non-proliferative tissues |
| CN113544509A (zh) | 2019-03-08 | 2021-10-22 | 牛津遗传学有限公司 | 选择抗体的方法 |
| AU2020270960B2 (en) | 2019-04-12 | 2026-01-29 | Ultragenyx Pharmaceutical Inc. | Engineered producer cell lines and methods of making and using the same |
| CA3138576A1 (en) | 2019-05-16 | 2020-11-19 | Trustees Of Boston University | Regulated synthetic gene expression systems |
| AU2020284255A1 (en) | 2019-05-30 | 2022-01-06 | Solid Biosciences Inc. | Recombinant herpesvirales vector |
| KR20220118436A (ko) | 2019-12-19 | 2022-08-25 | 론자 워커스빌 아이엔씨. | 바이러스 벡터의 자동화된 생산 |
| WO2021146591A2 (en) | 2020-01-17 | 2021-07-22 | Asklepios Biopharmaceutical, Inc. | Recombinant aav production |
| MX2022009560A (es) | 2020-02-04 | 2022-09-09 | Oxford Genetics Ltd | Proceso de fabricacion de vectores virales adenoasociados. |
| GB202001484D0 (en) | 2020-02-04 | 2020-03-18 | Oxford Genetics Ltd | DNA amplification method |
| JP2023518415A (ja) | 2020-03-19 | 2023-05-01 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 組換えａａｖにおいてｃａｐおよびｒｅｐ配列の逆パッケージングを低減するための組成物および方法 |
| JP2023526348A (ja) | 2020-05-15 | 2023-06-21 | アイヴェックスソル インコーポレイテッド | 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法 |
| CN113699147B (zh) | 2020-05-22 | 2023-06-09 | 深圳市深研生物科技有限公司 | 基于四环素和Cumate的共调控序列 |
| US20230279427A1 (en) | 2020-07-24 | 2023-09-07 | Regents Of The University Of Minnesota | Cell lines for recombinant aav production and aav-implemented protein production |
| WO2022038367A1 (en) | 2020-08-21 | 2022-02-24 | Oxford Genetics Limited | Process for making a recombinant aav library |
| GB202013057D0 (en) | 2020-08-21 | 2020-10-07 | Oxford Genetics Ltd | Method of making recombinant aavs |
| GB202013060D0 (en) | 2020-08-21 | 2020-10-07 | Oxford Genetics Ltd | Cell line |
| EP4006141A1 (en) | 2020-11-25 | 2022-06-01 | CEVEC Pharmaceuticals GmbH | Method for the production of aav |
| WO2022173944A1 (en) | 2021-02-11 | 2022-08-18 | Lonza Houston, Inc. | Adeno-associated virus (aav) production |
| WO2022223954A1 (en) | 2021-04-19 | 2022-10-27 | Oxford Genetics Limited | Dna amplification method using care elements |
| US20230257831A1 (en) | 2021-09-01 | 2023-08-17 | Oxford Genetics Limited | Method for determining aav titre |
| MX2024004691A (es) | 2021-10-18 | 2024-05-23 | Regeneron Pharma | Transcripcion controlada de polinucleotidos. |
| CA3235566A1 (en) | 2021-10-18 | 2023-04-27 | Michael Goren | Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites |
| WO2023173105A2 (en) | 2022-03-10 | 2023-09-14 | Saliogen Therapeutics, Inc. | Tetracycline inducer/repressor system and simplified viral particle production |
-
2022
- 2022-10-18 AU AU2022373653A patent/AU2022373653A1/en active Pending
- 2022-10-18 KR KR1020247016164A patent/KR20240099288A/ko active Pending
- 2022-10-18 MX MX2024004647A patent/MX2024004647A/es unknown
- 2022-10-18 JP JP2024522668A patent/JP2024537896A/ja active Pending
- 2022-10-18 WO PCT/US2022/078266 patent/WO2023069926A1/en not_active Ceased
- 2022-10-18 CN CN202280069671.6A patent/CN118103517A/zh active Pending
- 2022-10-18 TW TW111139399A patent/TW202323529A/zh unknown
- 2022-10-18 CA CA3234939A patent/CA3234939A1/en active Pending
- 2022-10-18 IL IL312124A patent/IL312124A/en unknown
- 2022-10-18 EP EP22818152.5A patent/EP4419696A1/en active Pending
- 2022-10-18 US US18/047,341 patent/US12234472B2/en active Active
-
2025
- 2025-01-15 US US19/022,099 patent/US20250154524A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3234939A1 (en) | 2023-04-27 |
| US20230193312A1 (en) | 2023-06-22 |
| EP4419696A1 (en) | 2024-08-28 |
| KR20240099288A (ko) | 2024-06-28 |
| JP2024537896A (ja) | 2024-10-16 |
| AU2022373653A1 (en) | 2024-05-02 |
| US20250154524A1 (en) | 2025-05-15 |
| IL312124A (en) | 2024-06-01 |
| US12234472B2 (en) | 2025-02-25 |
| WO2023069926A1 (en) | 2023-04-27 |
| TW202323529A (zh) | 2023-06-16 |
| CN118103517A (zh) | 2024-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ514951A (en) | Recombinant protein production in a cultured human cell | |
| Dautrevaux et al. | Structure covalente de la myoglobine de cheval | |
| ATE277947T1 (de) | Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung | |
| Klatt et al. | Molecular structure, processing, and tissue distribution of matrilin-4 | |
| WO2004075861A3 (en) | Recombinant adeno-associated virus production | |
| WO2019191633A3 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| WO2021198706A3 (en) | Coronavirus vaccines | |
| MX2024004647A (es) | Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus. | |
| EA201170993A1 (ru) | Удлиненные рекомбинантные полипептиды и содержащие их композиции | |
| DE60330923D1 (de) | Menschliche Koagulationsfaktor VII Polypeptide | |
| BR112017009177A2 (pt) | vacinas terapêuticas contra hpv16 | |
| WO2024073385A3 (en) | Synthetic polypeptides and uses thereof | |
| WO2021084276A3 (en) | Factor viii construct | |
| DE60036537D1 (de) | Zusammensetzungen zur gentherapie von diabetes | |
| MX2022014943A (es) | Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. | |
| ES2153358T3 (es) | Procedimientos para la seleccion de celulas huespedes recombinantes que expresan altos niveles de una proteina deseada. | |
| PH12021552609A1 (en) | Methods and compositions for transgene expression | |
| IL84700A (en) | Hybrid proteins,dnas coding therefor,hybrid vectors containing such dnas and hosts transformed therewith,the preparation of such hybrid proteins and pharmaceutical compositions containing them | |
| DE60118359D1 (de) | Humanische pellino-polypeptide | |
| HRP20020549B1 (hr) | Dna koja kodira novi rg1 polipeptid | |
| WO2005014775A3 (en) | Raav compositions and methods for delivery of human factor vii polypeptides and treatment of hemophilia a | |
| DE60235985D1 (de) | Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) | |
| MX2022013737A (es) | Nueva proteina y usos terapeuticos y cosmeticos de la misma. | |
| CR20230599A (es) | Composiciones y métodos para mejorar la función visual | |
| MX2023008595A (es) | Produccion mejorada de polipeptidos y virus recombinantes. |